The connection between Osimertinib, Osimertinib and Tagrisso

The relationship between Osimertinib and Tagrisso is actually the drug name and the trade name. The former is the generic name of the drug (International Nonproprietary Name, INN), while "Tagrisso" is the original trade name launched by AstraZeneca. This naming method is extremely common in the pharmaceutical field and helps medical staff use terminology in academic research and clinical practice. It also makes it easier for patients to identify brand-name drugs on the market.

Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI), mainly targeting non-small cell lung cancer (NSCLC) patients who carry EGFR sensitive mutations (such as Exon 19 deletion or L858R) and T790M resistance mutations. Its biggest innovation lies in its high selectivity for T790M resistance mutation and low inhibition of normal EGFR, making it a major breakthrough after the first-generation (such as gefitinib) and second-generation (such as afatinib) EGFR-TKI.

Clinically, osimertinib can be used both as an initial treatment and for patients who develop T790M resistance mutations after receiving first- and second-generation EGFR-TKI treatment. Because of its good brain penetration ability, it is also widely used in patients with brain metastases. Tagrisso, the brand name of osimertinib, has been approved for use in many countries and regions around the world since 2017, and was quickly included in the guideline recommended regimen for the treatment of EGFR mutations in non-small cell lung cancer.

Currently in China, "Tagressa" has been included in the national medical insurance directory, which has greatly reduced the financial burden of patients. Generic drugs of osimertinib have also begun to appear in the domestic market, and the price has further dropped, bringing hope to more patients. Although the names are different, both the medical term "osimertinib" and the market name "Tagressa" essentially refer to the same targeted drug. Before patients receive treatment, it is recommended to undergo EGFR mutation testing to confirm whether they are suitable for osimertinib/Tagressa, so as to achieve personalized and precise treatment. With more research.

Reference materials:https://go.drugbank.com/drugs/DB09330